cilostazol Tablets 50 mg, 100 mg
Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #3825
Established in 1994, this GMP manufacturer specializes in the development and production of CTD dossiers. As a CTD dossier owner and manufacturer, it ensures quality compliance across various markets. With GMP approvals, it showcases commitment to high standards. The manufacturer operates multiple production lines designed for diverse pharmaceutical formulations, catering to a wide range of needs. Its products are sold in over 25 countries and regions worldwide, supported by a dedicated team of around 300 employees. This GMP manufacturer excels as a CTD dossier owner and manufacturer, meeting global regulatory requirements efficiently.
Cilostazol is a medication used to treat intermittent claudication in peripheral vascular disease. Suppliers of cilostazol market it in the form of 50mg and 100mg tablets.
The drug was first introduced into the pharmaceutical market in 1999 and has since then become a widely prescribed medication with over a million prescriptions of cilostazol registered yearly in the U.S. alone. The largest manufacturers of cilostazol globally include GlaxoSmithKline, Bristol-Myers Squibb, Bedford Laboratories, Takeda, Novartis, Mylan, Abbot, and Pfizer.
Cilostazol suppliers and distributors market both generic and trade name formulations of the drug. Buyers are advised that online sellers may attempt to market fraudulent versions of the generic drug, whereas Pipeline Pharma, through its pre-auditing and quality control procedures ensures that only verified cilostazol manufacturers and wholesalers enter our online marketplace, offering you a risk-free B2B pharmaceutical sales platform.
The retail prices per 56 (100mg) tablets of cilostazol fall into an approximate range of 15,00 EUR to 20,00 EUR.